A randomized, double-blind, placebo controlled, phase 2 study of siRNA gene silencing for the treatment of non-alcoholic steatohepatitis (NASH) in participants with genetic risk factors
Using Gene Silencing to Treat Chronic Liver Disease Non-Alcoholic Steatohepatitis (NASH) in Adults at Increased Genetic Risk (NASHGEN-2)
Sponsor: Regeneron Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAV3431
U.S. Govt. ID: NCT05519475
Contact: Thresiamma Lukose: 212-305-7482 / tcrcstudyreferral@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine if an experimental drug, ALN-HSD, is safe and effective in patients diagnosed with non-alcoholic steatohepatitis (NASH), or metabolic dysfunction associated steatohepatitis (MASH) by improving liver function and lessening liver inflammation. This is a double-blind study, so the study doctors and participants will not know if they are receiving ALN-HSD or a placebo. Participation will last approximately 2 years.
Investigator
Julia Wattacheril, MD, MPH
Do You Qualify?
Are you at between 18 and 75 years old, inclusive) Yes No
Have you been diagnosed with non-alcoholic steatohepatitis (NASH) or Metabolic dysfunction-associated steatohepatitis (MASH)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Thresiamma Lukose
tcrcstudyreferral@cumc.columbia.edu
212-305-7482
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE